Literature DB >> 22140262

The cytokine midkine and its receptor RPTPζ regulate B cell survival in a pathway induced by CD74.

Sivan Cohen1, Or-yam Shoshana, Einat Zelman-Toister, Nitsan Maharshak, Inbal Binsky-Ehrenreich, Maya Gordin, Inbal Hazan-Halevy, Yair Herishanu, Lev Shvidel, Michal Haran, Lin Leng, Richard Bucala, Sheila Harroch, Idit Shachar.   

Abstract

Lasting B cell persistence depends on survival signals that are transduced by cell surface receptors. In this study, we describe a novel biological mechanism essential for survival and homeostasis of normal peripheral mature B cells and chronic lymphocytic leukemia cells, regulated by the heparin-binding cytokine, midkine (MK), and its proteoglycan receptor, the receptor-type tyrosine phosphatase ζ (RPTPζ). We demonstrate that MK initiates a signaling cascade leading to B cell survival by binding to RPTPζ. In mice lacking PTPRZ, the proportion and number of the mature B cell population are reduced. Our results emphasize a unique and critical function for MK signaling in the previously described MIF/CD74-induced survival pathway. Stimulation of CD74 with MIF leads to c-Met activation, resulting in elevation of MK expression in both normal mouse splenic B and chronic lymphocytic leukemia cells. Our results indicate that MK and RPTPζ are important regulators of the B cell repertoire. These findings could pave the way toward understanding the mechanisms shaping B cell survival and suggest novel therapeutic strategies based on the blockade of the MK/RPTPζ-dependent survival pathway.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22140262      PMCID: PMC3244541          DOI: 10.4049/jimmunol.1101468

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase.

Authors:  S L Pogue; T Kurosaki; J Bolen; R Herbst
Journal:  J Immunol       Date:  2000-08-01       Impact factor: 5.422

2.  LDL receptor-related protein as a component of the midkine receptor.

Authors:  H Muramatsu; K Zou; N Sakaguchi; S Ikematsu; S Sakuma; T Muramatsu
Journal:  Biochem Biophys Res Commun       Date:  2000-04-21       Impact factor: 3.575

3.  Midkine rescues Wilms' tumor cells from cisplatin-induced apoptosis: regulation of Bcl-2 expression by Midkine.

Authors:  M Qi; S Ikematsu; K Ichihara-Tanaka; S Sakuma; T Muramatsu; K Kadomatsu
Journal:  J Biochem       Date:  2000-02       Impact factor: 3.387

4.  Midkine inhibits caspase-dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons.

Authors:  K Owada; N Sanjo; T Kobayashi; H Mizusawa; H Muramatsu; T Muramatsu; M Michikawa
Journal:  J Neurochem       Date:  1999-11       Impact factor: 5.372

5.  Invariant chain induces B cell maturation by activating a TAF(II)105-NF-kappaB-dependent transcription program.

Authors:  D Matza; O Wolstein; R Dikstein; I Shachar
Journal:  J Biol Chem       Date:  2001-05-22       Impact factor: 5.157

6.  Invariant chain-induced B cell differentiation requires intramembrane proteolytic release of the cytosolic domain.

Authors:  Didi Matza; Anat Kerem; Helena Medvedovsky; Frida Lantner; Idit Shachar
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

7.  Invariant chain expression in gastric cancer.

Authors:  S Ishigami; S Natsugoe; K Tokuda; A Nakajo; H Iwashige; K Aridome; S Hokita; T Aikou
Journal:  Cancer Lett       Date:  2001-07-10       Impact factor: 8.679

8.  No obvious abnormality in mice deficient in receptor protein tyrosine phosphatase beta.

Authors:  S Harroch; M Palmeri; J Rosenbluth; A Custer; M Okigaki; P Shrager; M Blum; J D Buxbaum; J Schlessinger
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

9.  Midkine expression in Reed-Sternberg cells of Hodgkin's disease.

Authors:  H Kato; K Watanabe; M Murari; C Isogai; T Kinoshita; H Nagai; H Ohashi; T Nagasaka; K Kadomatsu; H Muramatsu; T Muramatsu; H Saito; N Mori; T Murate
Journal:  Leuk Lymphoma       Date:  2000-04

10.  Serum midkine levels are increased in patients with various types of carcinomas.

Authors:  S Ikematsu; A Yano; K Aridome; M Kikuchi; H Kumai; H Nagano; K Okamoto; M Oda; S Sakuma; T Aikou; H Muramatsu; K Kadomatsu; T Muramatsu
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

View more
  22 in total

Review 1.  Structure and function of midkine as the basis of its pharmacological effects.

Authors:  T Muramatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

2.  Novel Biological Substrates of Human Kallikrein 7 Identified through Degradomics.

Authors:  Yijing Yu; Ioannis Prassas; Apostolos Dimitromanolakis; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2015-06-01       Impact factor: 5.157

Review 3.  Midkine as a regulator of B cell survival in health and disease.

Authors:  Sivan Cohen; Idit Shachar
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

4.  Midkine is a dual regulator of wound epidermis development and inflammation during the initiation of limb regeneration.

Authors:  Stephanie L Tsai; Clara Baselga-Garriga; Douglas A Melton
Journal:  Elife       Date:  2020-01-14       Impact factor: 8.140

5.  CD74 is a novel transcription regulator.

Authors:  Naama Gil-Yarom; Lihi Radomir; Lital Sever; Matthias P Kramer; Hadas Lewinsky; Chamutal Bornstein; Ronnie Blecher-Gonen; Zohar Barnett-Itzhaki; Vita Mirkin; Gilgi Friedlander; Lev Shvidel; Yair Herishanu; Elias J Lolis; Shirly Becker-Herman; Ido Amit; Idit Shachar
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-28       Impact factor: 11.205

Review 6.  From top to bottom: midkine and pleiotrophin as emerging players in immune regulation.

Authors:  Noah Sorrelle; Adrian T A Dominguez; Rolf A Brekken
Journal:  J Leukoc Biol       Date:  2017-03-29       Impact factor: 4.962

Review 7.  Immunoregulatory properties of the cytokine IL-34.

Authors:  Carole Guillonneau; Séverine Bézie; Ignacio Anegon
Journal:  Cell Mol Life Sci       Date:  2017-03-03       Impact factor: 9.261

Review 8.  Therapeutic potential of midkine in cardiovascular disease.

Authors:  Kenji Kadomatsu; Péter Bencsik; Anikó Görbe; Csaba Csonka; Kazuma Sakamoto; Satoshi Kishida; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 9.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

Review 10.  Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.

Authors:  Panagiota S Filippou; George S Karagiannis; Anastasia Constantinidou
Journal:  Oncogene       Date:  2019-12-04       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.